Skyrizi (risankizumab) is a prescription medication used to treat plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the interleukin-23 (IL-23) pathway, which is involved in the development and progression of psoriasis.
Uses
Skyrizi is used to treat plaque psoriasis in adults. Plaque psoriasis is a chronic autoimmune disease that causes red, scaly patches of skin to form. Skyrizi can help to clear these patches and improve the appearance and comfort of the skin.
Storage Conditions
Skyrizi should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Skyrizi can be kept at room temperature for up to 24 hours.
Mechanism of Action
Skyrizi is a monoclonal antibody that binds to the p19 subunit of IL-23 and blocks its interaction with the IL-23 receptor. IL-23 is a cytokine that plays a key role in the development and progression of psoriasis. By blocking IL-23, Skyrizi can help to reduce inflammation and improve the symptoms of psoriasis.
How to Use
Skyrizi is administered by subcutaneous injection every 12 weeks. The recommended dose is 150 mg. Skyrizi should be injected by a healthcare professional.
Important Safety Information
Skyrizi can increase the risk of serious infections, including tuberculosis. Before starting Skyrizi, your doctor will test you for tuberculosis. Skyrizi can also reactivate latent tuberculosis infection.
Skyrizi can also increase the risk of other side effects, such as:
- Allergic reactions
- Inflammatory bowel disease (IBD)
- Psoriasis worsening
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Diarrhea
- Nausea
- Fatigue
Indications
Skyrizi is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Precautions
Skyrizi should be used with caution in patients with a history of serious infections, tuberculosis, IBD, or other autoimmune diseases.
Skyrizi should not be used in patients who have a history of severe allergic reactions to Skyrizi or other biologic medications.
Interactions
Skyrizi may interact with other medications, including live vaccines and biologic medications. Be sure to tell your doctor about all of the medications you are taking before starting Skyrizi.
Contraindications
Skyrizi is contraindicated in patients with a history of severe allergic reactions to Skyrizi or other biologic medications.
Overdose
There is no known overdose of Skyrizi.
Side Effects
The most common side effects of Skyrizi are upper respiratory tract infections, headache, diarrhea, nausea, fatigue, and injection site reactions.
More serious side effects of Skyrizi include serious infections, IBD, psoriasis worsening, and allergic reactions.
If you experience any side effects while taking Skyrizi, be sure to tell your doctor.
Additional Information
Skyrizi was approved by the U.S. Food and Drug Administration (FDA) in 2019.
Reviews
There are no reviews yet.